Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer

Biomaterials. 2009 Feb;30(6):1184-96. doi: 10.1016/j.biomaterials.2008.10.060. Epub 2008 Dec 1.

Abstract

The effects of fullerenol C60(OH)24 (Frl) at doses of 25, 50, and 100mg/kg/week (for a time-span of 3 weeks) on heart and liver tissue after doxorubicin (Dox)-induced toxicity in rats with colorectal cancer were investigated. In the present study, we used an in vivo Wistar male rat model to explore whether Frl could protect against Dox-induced (1.5mg/kg/week for 3 weeks) chronic cardio- and hepato- toxicity and compared the effect with a well-known antioxidant, vitamin C (100mg/kg/week for 3 weeks). According to macroscopic, microscopic, hematological, biochemical, physiological, pharmacological, and pharmacokinetic results, we confirmed that, at all examined doses, Frl exhibits a protective influence on the heart and liver tissue against chronic toxicity induced by Dox.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Cavity / pathology
  • Animals
  • Body Weight / drug effects
  • Cardiotoxins / toxicity
  • Colorectal Neoplasms / blood
  • Colorectal Neoplasms / enzymology
  • Colorectal Neoplasms / pathology*
  • Doxorubicin / toxicity*
  • Electrocardiography
  • Enzymes / blood
  • Fullerenes / pharmacokinetics
  • Fullerenes / pharmacology*
  • Glutathione Disulfide / metabolism
  • Heart / drug effects*
  • Hemodynamics / drug effects
  • Liver / drug effects*
  • Liver / pathology
  • Male
  • Malondialdehyde / metabolism
  • Myocardium / pathology
  • Oxidation-Reduction / drug effects
  • Oxidative Stress / drug effects
  • Protective Agents / pharmacology*
  • Rats
  • Rats, Wistar

Substances

  • Cardiotoxins
  • Enzymes
  • Fullerenes
  • Protective Agents
  • fullerenol
  • Malondialdehyde
  • Doxorubicin
  • Glutathione Disulfide